A gel-free MS-based quantitative proteomic approach accurately measures cytochrome P450 protein concentrations in human liver microsomes

Proteomics

Volumn 8, Issue 20, 2008, Pages 4186-4196

  Wang, Michael Zhuo ^a   Wu, Judy Qiju ^b   Dennison, Jennifer B ^c   Bridges, Arlene S ^a   Hall, Stephen D ^c   Kornbluth, Sally ^b   Tidwell, Richard R ^a,d   Smith, Philip C ^a   Voyksner, Robert D ^e   Paine, Mary F ^a   Hall, James Edwin ^a,d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e LCMS Limited   (United States)

Author keywords

Absolute quantification; CYP3A; Cytochrome P450; LC MS MS; Pharmacoproteomics

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ISOTOPE; ITRACONAZOLE; PEPTIDE; RECOMBINANT PROTEIN; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CALIBRATION; CHILD; CONCENTRATION (PARAMETERS); DRUG HYDROXYLATION; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE LABELING; LIVER MICROSOME; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STANDARD;

ADOLESCENT; ADULT; AGED; CHILD; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; MIDDLE AGED; PROTEOMICS; SEQUENCE HOMOLOGY, AMINO ACID; UNCERTAINTY;

EID: 55749097752     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200800144     Document Type: Article

References (30)

1. Guengerich, F. P., in: Ortiz de Montellano, P. R. (Ed.), Cytochrome P450 Structure, Mechanism, and Biochemistry, Kluwer Academic/Plenum Publishers, New York 2005, pp. 377-530.
2. Wilkinson, G. R., Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 2005, 352, 2211-2221.
3. Alterman, M. A., Kornilayev, B., Duzhak, T., Yakovlev, D., Quantitative analysis of cytochrome p450 isozymes by means of unique isozyme-specific tryptic peptides: a proteomic approach. Drug Metab. Dispos. 2005, 33, 1399-1407.
4. Gerber, S. A., Rush, J., Stemman, O., Kirschner, M. W., Gygi, S. P., Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. USA 2003, 100, 6940-6945.
5. Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B. et al., Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3, 1154-1169.
6. Barnidge, D. R., Dratz, E. A., Martin, T., Bonilla, L. E. et al., Absolute quantification of the G protein-coupled receptor rhodopsin by LC/MS/MS using proteolysis product peptides and synthetic peptide standards. Anal. Chem. 2003, 75, 445-451.
7. Wang, Y., Al-Gazzar, A., Seibert, C., Sharif, A. et al., Proteomic analysis of cytochromes P450: a mass spectrometry approach. Biochem. Soc. Trans. 2006, 34, 1246-1251.
8. Jenkins, R. E., Kitteringham, N. R., Hunter, C. L., Webb, S. et al., Relative and absolute quantitative expression profiling of cytochromes P450 using isotope-coded affinity tags. Proteomics 2006, 6, 1934-1947.
9. Lane, C. S., Wang, Y., Betts, R., Griffiths, W. J., Patterson, L. H., Comparative cytochrome P450 proteomics in the livers of immunodeficient mice using 18O stable isotope labeling. Mol. Cell. Proteomics 2007, 6, 953-962.
10. Barr, J. R., Maggio, V. L., Patterson, D. G., Jr., Cooper, G. R. et al., Isotope dilution-mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin. Chem. 1996, 42, 1676-1682.
11. Thummel, K. E., Wilkinson, G. R., In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 1998, 38, 389-430.
12. Dennison, J. B., Jones, D. R., Renbarger, J. L., Hall, S. D., Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J. Pharmacol. Exp. Ther. 2007, 321, 553-563.
13. Omura, T., Sato, R., The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 1964, 239, 2370-2378.
14. Rosenfeld, J., Capdevielle, J., Guillemot, J. C., Ferrara, P., Ingel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis. Anal. Biochem. 1992, 203, 173-179.
15. Wierenga, S. K., Zocher, M. J., Mirus, M. M., Conrads, T. P. et al., A method to evaluate tryptic digestion efficiency for high-throughput proteome analyses. Rapid Commun. Mass Spectrom. 2002, 16, 1404-1408.
16. Wang, M. Z., Wu, J. Q., Bridges, A. S., Zeldin, D. C. et al., Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab. Dispos. 2007, 35, 2067-2075.
17. Isoherranen, N., Kunze, K. L., Allen, K. E., Nelson, W. L., Thummel, K. E., Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab. Dispos. 2004, 32, 1121-1131.
18. Dennison, J. B., Kulanthaivel, P., Barbuch, R. J., Renbarger, J. L. et al., Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab. Dispos. 2006, 34, 1317-1327.
19. Nebert, D. W., Russell, D. W., Clinical importance of the cytochromes P450. Lancet 2002, 360, 1155-1162.
20. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., Guengerich, F. P., Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270, 414-423.
21. Kuhn, E., Wu, J., Karl, J., Liao, H. et al., Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 2004, 4, 1175-1186.
22. Galetin, A., Brown, C., Hallifax, D., Ito, K., Houston, J. B., Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. Drug Metab. Dispos. 2004, 32, 1411-1420.
23. King, B. P., Leathart, J. B., Mutch, E., Williams, F. M., Daly, A. K., CYP3A5 phenotype-genotype correlations in a British population. Br. J. Clin. Pharmacol. 2003, 55, 625-629.
24. Wang, Y. H., Jones, D. R., Hall, S. D., Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab. Dispos. 2005, 33, 664-671.
25. Perrett, H. F., Barter, Z. E., Jones, B. C., Yamazaki, H. et al., Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes. Drug Metab. Dispos. 2007, 35, 1733-1736.
26. Kirkpatrick, D. S., Gerber, S. A., Gygi, S. P., The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods 2005, 35, 265-273.
27. Vogt, W., Oxidation of methionyl residues in proteins: tools, targets, and reversal. Free Radic. Biol. Med. 1995, 18, 93-105.
28. Bardwell, J., Thiol modifications in a snapshot. Nat. Biotechnol. 2005, 23, 42-43.
29. Kalsotra, A., Strobel, H. W., Cytochrome P450 4F subfamily: At the crossroads of eicosanoid and drug metabolism. Pharmacol. Ther. 2006, 112, 589-611.
30. Wang, M. Z., Saulter, J. Y., Usuki, E., Cheung, Y. L. et al., CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl) furanbis-O-methylamidoxime]. Drug Metab. Dispos. 2006, 34, 1985-1994.